ArticleCNS neuroscience & therapeutics2025
Differences in Glucose Metabolism Between Single Memory Domain and Multidomain Subjective Cognitive Decline: A Longitudinal Study From SILCODE.
Article in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundGlucose metabolism and plasma biomarkers have emerged as important early markers in Alzheimer's disease. Different subtypes (single memory domain, multidomain) of subjective cognitive decline (SCD) may represent distinct stages of disease progression, but the differences in glucose metabolism remain unclear. This study focused on exploring the differences in glucose metabolism between different SCD subtypes and the correlation with plasma biomarkers based on
methodsIn this study, thirty-three normal controls (NCs), thirty-five individuals with single memory domain SCD (sd-SCD), thirty-nine individuals with multidomain SCD (md-SCD), and twenty-one cognitively impaired (CI) individuals were involved. We investigated the standardized uptake value ratio (SUVR) and voxel differences between the sd-SCD and md-SCD groups followed by FDR and GRF corrections, with an average follow-up time of 44.98 ± 16.49 months. Correlation analyses were employed to assess relationships between FDG-PET SUVR and neuropsychological scales as well as plasma biomarkers. Finally, Kaplan-Meier survival analysis was used to investigate the risk of cognitive decline conversion among SCD subgroups.
resultsAfter controlling for the effects of covariates, the following brain regions showed voxel differences and lower SUVR in md-SCD groups, including right anterior cingulate and paracingulate gyri (ACG.R, p = 0.003), left anterior cingulate and paracingulate gyri (ACG.L, p = 0.003), right middle temporal gyrus (MTG.R, p = 0.004), and right inferior temporal gyrus (ITG.R, p = 0.001), compared to the sd-SCD group. SUVR of ACG.R was correlated with plasma Aβ42/40 (r = 0.435, p = 0.006) and AVLT-N7 score (r = 0.347, p = 0.031) in the md-SCD group while none of the correlations existed in the sd-SCD group. SUVR of MTG.R was also correlated with the AVLT-N7 score (r = 0.246, p = 0.035) across SCD individuals. The SCD individuals with positive plasma Aβ42/40, p-tau181, and glucose metabolism in above four regions, or those in the md-SCD group showed an elevated risk of cognitive conversion in comparison to the controls.
conclusionsDifferences in glucose metabolism could be observed between the md-SCD and sd-SCD groups. SCD participants in the md-SCD group, or those with positive biomarkers, might represent a higher risk of cognitive decline conversion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.